Antitumorigenic effects of tamoxifen, raloxifene and the combination on the development of breast tumors induced by mouse mammary carcinoma cells in balb/c-J female mice.
The antitumorigenic efficacy of tamoxifen, raloxifene, and their combination was evaluated on 4t1 estrogen-positive murine mammary carcinoma cells by determining their ability in breast tumor development in balb/c-J female mice. Each mouse received intraperitoneally 0.1 ml of pbS solvent containing no drug, 12 mg (0.6 mg/kg) of tamoxifen, 36 mg (1.8 mg/kg) of raloxifene, or the combination of the two drugs (12 mg tamoxifen + 36 mg raloxifene) at 48-hour intervals for 35 days. Drug concentrations used were equivalent to human doses. within the study period of 35 days, tamoxifen demonstrated the greatest effectiveness, as it allowed "progression-free survival," increased mouse life span by an average of 6 days, had the greatest number of survivors (90.9%), and those with the smallest spleen weight and volume. Raloxifene and combination groups, compared to the drug-untreated mice, did not significantly lengthen the life span or survivability, produced grossly enlarged spleens, and mice exhibited maladies such as leg paralysis and acute lethargy.
Goel
A J
AJ
Department of Biology, Lafayette College, Easton, PA 18042, USA.
Majumdar
S K
SK
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage; D014407:Tumor Cells, Cultured
D013629:Tamoxifen; D020849:Raloxifene Hydrochloride